Thursday, April 02, 2020 6:16:35 PM
I'm all-in on TEVA,
two accounts; Ind and Sep, so I have to applaud your choice, but ...
My trading style is both Shield and Sword and I try my best to thoroughly study the opponent: most often I buy shares (the sword) then sell weekly CCs (the shield) against those shares. Immediately, that provides income -- therefore risk is reduced. That comes with another kind of risk: selling the Calls too soon and missing a better swing higher. But I don’t often complain because doing the math and compounding weekly gains always yields over 100% gains every year if the right stock is chosen. When the right stock is not right anymore, pick a different one after doing a little homework.
Trading TEVA at present -- because it has good earnings, and being a healthcare drug stock -- ought to do pretty well while everybody is worried about becoming ill and needing medication. To me that's a slap-my-forehead-and-utter-duh! moment.
Being an all-in trader, I watch TEVA very closely [one-minute intraday charts, SMA(26)-SMA(65) trends and crossovers, and intraday pivots and their support and resistance and crossovers by the stock itself]. Also, at the one-minute level, traders seem to have price preferences that represent integer multiples of nickels and dimes so those can also become support and resistance levels. Though 30-min candles are commonly the choice of intraday traders, that's too long for me. I prefer to watch minute by minute how the trade evolves during the day and how it interacts with the things I mentioned above.
two accounts; Ind and Sep, so I have to applaud your choice, but ...
My trading style is both Shield and Sword and I try my best to thoroughly study the opponent: most often I buy shares (the sword) then sell weekly CCs (the shield) against those shares. Immediately, that provides income -- therefore risk is reduced. That comes with another kind of risk: selling the Calls too soon and missing a better swing higher. But I don’t often complain because doing the math and compounding weekly gains always yields over 100% gains every year if the right stock is chosen. When the right stock is not right anymore, pick a different one after doing a little homework.
Trading TEVA at present -- because it has good earnings, and being a healthcare drug stock -- ought to do pretty well while everybody is worried about becoming ill and needing medication. To me that's a slap-my-forehead-and-utter-duh! moment.
Being an all-in trader, I watch TEVA very closely [one-minute intraday charts, SMA(26)-SMA(65) trends and crossovers, and intraday pivots and their support and resistance and crossovers by the stock itself]. Also, at the one-minute level, traders seem to have price preferences that represent integer multiples of nickels and dimes so those can also become support and resistance levels. Though 30-min candles are commonly the choice of intraday traders, that's too long for me. I prefer to watch minute by minute how the trade evolves during the day and how it interacts with the things I mentioned above.
Recent TEVA News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/30/2026 08:40:45 PM
- Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 08:06:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:00:20 AM
- Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy • GlobeNewswire Inc. • 04/29/2026 10:30:00 AM
- Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics • GlobeNewswire Inc. • 04/14/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 08:43:03 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/31/2026 08:41:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/31/2026 08:38:29 PM
- Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026 • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Teva Releases Q1 2026 Aide Memoire • GlobeNewswire Inc. • 03/19/2026 08:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:36:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:28:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:22:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:46:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:34:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:25:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:13:29 PM
- Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug • GlobeNewswire Inc. • 03/03/2026 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2026 09:01:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2026 09:11:04 PM
- Teva to Present at the Upcoming Investor Conferences in March • GlobeNewswire Inc. • 02/24/2026 09:30:00 PM
